Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats

Drug Metabolism and Disposition

Volumn 37, Issue 8, 2009, Pages 1622-1634

  Fukano, Y ^a   Kawazu, K ^a  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DINOR TRAFLUPROST ACID; 1,2,3,4 TETRANOR TAFLUPROST ACID; 1,2,3,4 TETRANOR TAFLUPROST ACID LACTONE; DRUG METABOLITE; TAFLUPROST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CILIARY BODY; CONTROLLED STUDY; CORNEA; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; LIQUID SCINTILLATION COUNTING; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SEX DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; DOGS; EYE; FECES; FEMALE; GLAUCOMA; GLUCURONIDES; HEPATOCYTES; HUMANS; HYDROLYSIS; INJECTIONS, INTRAVENOUS; LACTATION; MACACA FASCICULARIS; MALE; METABOLOMICS; MILK; OPHTHALMIC SOLUTIONS; PLACENTA; PREGNANCY; PRODRUGS; PROSTAGLANDINS F; RATS; RATS, SPRAGUE-DAWLEY; SEX FACTORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; TRITIUM;

RATTUS;

EID: 67650831248     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.024885     Document Type: Article

References (24)

1. 2α esters across cornea in vitro. Int J Pharm 29:259-266.
2. 2α and its isopropyl ester in vitro. Int J Pharm 37:27-32.
3. Higaki K, Kamata K, Takeuchi M, Inazawa K, Chikai T, Hamaguchi T, Yukawa T, Kadono K, Kawahara S, and Nakano M (1995) Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits. Drug Metab Dispos 23:35-43.
4. Ishida N, Odani-Kawabata N, Shimazaki A, and Hara H (2006) Prostanoids in the therapy of glaucoma. Cardiovasc Drug Rev 24:1-10.
5. Johnson M, Davison P, and Ramwell PW (1972) Carnitine-dependent β oxidation of prostaglandins. J Biol Chem 247:5656-5658.
6. 2α lowers intraocular pressure. Prog Clin Biol Res 312:387-416.
7. Madhu C, Rix P, Nguyen T, Chien DS, Woodward DF, and Tang-Liu DD (1998) Penetration of natural prostaglandins and their ester prodrugs and analogs across human ocular tissues in vitro. J Ocul Pharmacol Ther 14:389-399.
8. 2α derivative. Tetrahedr Lett 45:1527-1529.
9. 2α derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull 26:1691-1695.
10. 2α-1-isopropylester in the cynomolgus monkey. Exp Eye Res 48:707-716.
11. Redell MA, Yang DC, and Lee VHL (1983) The role of esterase activity in the ocular disposition of dipivalyl epinephrine in rabbits. Int J Pharm 17:299-312.
12. Richmond CR, Langham WH, and Trujillo TT (1962) Comparative metabolism of tritiated water by mammals. J Cell Comp Physiol 59:45-53.
13. Scherer WJ (2002) A retrospective review of non-responders to latanoprost. J Ocul Pharmacol Ther 18:287-291.
14. 3H]9β-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol 51:685-694.
15. Sjöquist B, Basu S, Byding P, Bergh K, and Stjernschantz J (1998) The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab Dispos 26:745-754.
16. Sjöquist B, Uhlin A, Byding P, and Stjernschantz J (1999) Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye. Arzneimittelforschung 49:234-239.
17. 2α analogue. Adv Prostaglandin Thromboxane Leukot Res 23:513-518.
18. Sutton A, Gilvarry A, and Ropo A (2007) A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males. J Ocul Pharmacol Ther 23:359-365.
19. Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, Gabelt BT, Kaufman PL, and Hara H (2004) Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res 78:767-776.
20. Taniguchi T, Haque MS, Sugiyama K, Hori N, and Kitazawa Y (1996) Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits. J Ocul Pharmacol Ther 12:489-498.
21. Walsh JS, Patanella JE, Halm KA, and Facchine KL (1995) An improved HPLC assay for the assessment of liver slice metabolic viability using 7-ethoxycoumarin. Drug Metab Dispos 23:869-874.
22. Watson PG (1998) Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 105:82-87.
23. Wilson JT, Brown RD, Cherek DR, Dailey JW, Hilman B, Jobe PC, Manno BR, Manno JE, Redetzki HM, and Stewart JJ (1980) Drug excretion in human breast milk. Clin Pharmacokinet 5:1-66.
24. Woodward DF, Krauss AH-P, Chen J, Lai RK, Spada CS, Burk RM, Andrews SW, Shi L, Liang Y, Kedzie KM, et al. (2001) The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 45:S337-S345.